436 related articles for article (PubMed ID: 30011788)
1. Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia.
Kosmas CE; Muñoz Estrella A; Sourlas A; Silverio D; Hilario E; Montan PD; Guzman E
Diseases; 2018 Jul; 6(3):. PubMed ID: 30011788
[TBL] [Abstract][Full Text] [Related]
2. Inclisiran for the treatment of dyslipidemia.
Nishikido T; Ray KK
Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410
[TBL] [Abstract][Full Text] [Related]
3. Inclisiran in dyslipidemia.
Kosmas CE; Muñoz Estrella A; Sourlas A; Pantou D
Drugs Today (Barc); 2021 May; 57(5):311-319. PubMed ID: 34061126
[TBL] [Abstract][Full Text] [Related]
4. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
5. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
Warden BA; Duell PB
J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
[TBL] [Abstract][Full Text] [Related]
6. A Critical Review of the Efficacy and Safety of Inclisiran.
Hardy J; Niman S; Pereira E; Lewis T; Reid J; Choksi R; Goldfaden RF
Am J Cardiovasc Drugs; 2021 Nov; 21(6):629-642. PubMed ID: 33954930
[TBL] [Abstract][Full Text] [Related]
7. Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9.
German CA; Shapiro MD
BioDrugs; 2020 Feb; 34(1):1-9. PubMed ID: 31782112
[TBL] [Abstract][Full Text] [Related]
8. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
Sinning D; Landmesser U
Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
[TBL] [Abstract][Full Text] [Related]
9. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
10. Emerging biologic therapies for hypercholesterolaemia.
Pucci G; Cicero AF; Borghi C; Schillaci G
Expert Opin Biol Ther; 2017 Sep; 17(9):1077-1087. PubMed ID: 28617192
[TBL] [Abstract][Full Text] [Related]
11. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
12. Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential.
Kosmas CE; Muñoz Estrella A; Skavdis A; Peña Genao E; Martinez I; Guzman E
Ther Clin Risk Manag; 2020; 16():1031-1037. PubMed ID: 33149595
[TBL] [Abstract][Full Text] [Related]
13. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia.
Luo Z; Huang Z; Sun F; Guo F; Wang Y; Kao S; Yang G; Huang J; Li J; Zhao S; He Y
J Clin Lipidol; 2023; 17(3):392-400. PubMed ID: 37164838
[TBL] [Abstract][Full Text] [Related]
14. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
[TBL] [Abstract][Full Text] [Related]
15. Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a).
Katsiki N; Vrablik M; Banach M; Gouni-Berthold I
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111334
[TBL] [Abstract][Full Text] [Related]
16. Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia.
Ebenezer O; Comoglio P; Wong GK; Tuszynski JA
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835426
[TBL] [Abstract][Full Text] [Related]
17. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
18. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
[TBL] [Abstract][Full Text] [Related]
19. Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy.
Kosmas CE; DeJesus E; Morcelo R; Garcia F; Montan PD; Guzman E
Drugs Context; 2017; 6():212511. PubMed ID: 29209403
[TBL] [Abstract][Full Text] [Related]
20. Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction.
Smith KW; White CM
J Clin Pharmacol; 2022 Sep; 62(9):1079-1085. PubMed ID: 35279835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
